Efficacy of up-front 5-fluorouracil - Epidoxorubicin - cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1080-1085

  Van Der Wall, E ^a,b   Rutgers, E J T ^a   Holtkamp, M J ^a   Baars, J W ^a   Schornagel, J H ^a   Peterse, J L ^a   Beijnen, J H ^a   Rodenhuis, S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; High dose epidoxorubicin; Up front chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; ALOPECIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MASTECTOMY; MICROSCOPE IMAGE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGE FACTORS; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION;

EID: 0029972405     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.208     Document Type: Article

References (34)

1. BEAHRS OH, HENSON DE, HUTTER RVP AND KENNEDY BJ (EDS). (1993). In Manual for Staging of Cancer, 4th edn, pp. 161-167, JB Lippincott: Philadelphia.
2. BÉLEMBAOGO E, FEILLEL V, CHOLLET P, CURÉ H, VERRELLE P, KWIATKOWSKI F, ACHARD JL, LE BOUËDEC, CHASSAGNE J, BIGNON YJ, DE LATOUR M, LAFAYE C AND DAUPLAT J. (1992). Neoadjuvant chemotherapy in 126 operable breast cancers. Eur. J. Cancer, 28A, 896-900.
3. BONADONNA G, VERONESI U, BRAMBILLA C, FERRARI L, LUINI A, GRECO M, BARTOLI C, COOPMANS DE YOLDI G, ZUCALI R, RILKE F, ANDREOLA S, SILVESTRINI R, DI FRONZO G AND VALAGUSSA P. (1990). Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl Cancer Inst., 82, 1539-1545.
4. BONNADONNA G, GIANNI L, SANTORO A, BONFANTE V, BIDOLI P, CASALI P, DEMICHELLE R AND VALAGUSSA P. (1993). Drugs ten years later: Epirubicin. Ann. Oncol., 4, 359-369.
5. BORGER JH, VAN TIENHOVEN G, PASSCHIER DH, HART AAM, VAN DONGEN JA, RUTGERS EJT AND BARTELINK H. (1992). Primary radiotherapy of breast cancer: treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy. Radiother. Oncol., 25, 1-11.
6. CALAIS G, BERGER C, DESCAMPS P, CHAPERT S, REYNAUD-BOUGNOUX A, BODY G, BOUGNOUX P, LANSAC J AND LE FLOCH O. (1994). Conservative treatment feasibility with induction chemotherapy, surgery and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer, 74, 1283-1288.
7. CHEVALLIER B, ROCHE H, OLIVIER JP, CHOLLET P AND HURTELOUP P. (1993). Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol., 16, 223-228.
8. VAN DONGEN JA. (1977). Subclavicular biopsy as a guideline for the treatment of breast cancer. World J. Surg., 1, 306-308.
9. ELIAS EG, VACHON DA, DIDOLKAR MS AND AISNER J. (1991). Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast. Am. J. Surg., 162, 231-235.
10. FISHER B AND MAMOUNAS EP. (1995). Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J. Clin. Oncol., 13, 537-540.
11. FISHER B, GUNDUZ N AND SAFFER EA. (1983). Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res., 43, 1488-1492.
12. FISHER B, SAFFER EA, RUDOCK C, COYLE J AND GUNDUZ N. (1989). Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res., 49, 2002-2004.
13. FOCAN C, ANDRIEN JM, CLOSON MTH, DICATO M, DRIESSCHAERT P, FOCAN-HENRAD D, LEMAIRE M, LOBELLE JP, LONGREE L AND REIS F. (1993). Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J. Clin. Oncol., 11, 1253-1263.
14. HAAGENSEN CD AND STOUT AP. (1943). Carcinoma of the breast, 11 criteria of operability. Ann. Surg., 118, 859-868.
15. HABESHAW T, PAUL J, JONES R, STALLARD S, STEWART M, KAYE SB, SOUKOP M, SYMONDS RP, REED NS AND RANKIN EM. (1991). Epirubicin at 2 dose levels with prednisolone as treatment for advanced breast cancer. The results of a randomized trial. J. Clin. Oncol., 9, 295-304.
16. ITALIAN MULTICENTRE BREAST STUDY WITH EPIRUBICIN. (1988). Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide versus fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian Multicentre Trial. J. Clin. Oncol., 6, 976-982.
17. MCGUIRE WL, DE LA GARZA M AND CHAMNESS GC. (1977). Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res., 37, 637-639.
18. MAURIAC L, DURAND M, AVRIL A AND DIHUYDY JM. (1991). Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann. Oncol., 2, 347-354.
19. MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A. (1981). Reporting results of cancer treatment. Cancer, 47, 207-214.
20. MOORE MAS. (1992). Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood, 80, 3-7.
21. MOSKOVIC EC, MANSI JL, KING DM, MURCH CR AND SMITH IE. (1993). Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin. Radiol., 47, 339-344.
22. PEREZ CA, GRAHAM ML, TAYLOR ME, LEVY JF, MORTIMER JE, PHILPOTT GW AND KUCIK NA. (1994). Management of locally advanced carcinoma of the breast. Cancer, 74, 453-465.
23. PERLOFF M, LESNICK GJ, KORZON A, CHU F, HOLLAND JF, THIRWELL MP, ELLISON RR, CAREY RW, LEONE L, WEINBERG V, RICE MA AND WOOD WC. (1988). Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a cancer and leukemia group B study. J. Clin. Oncol., 6, 261-269.
24. RODENHUIS S, BAARS JW, SCHORNAGEL JH, VLASVELD LT, MANDJES I, PINEDO HM AND RICHEL DJ. (1992). Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann. Oncol., 3, 855-860.
25. RUBENS RD. (1978). Systemic therapy combined with radiotherapy for primary inoperable carcinoma of the breast. In Application of Cancer Chemotherapy. Antibiotics Chemother. Karger, Basle, 24, 205-212.
26. RUBENS RD, BARTELINK H, ENGELSMAN E, HAYWARD JL, ROTMENSZ N, SYLVESTER R, VAN DER SCHUEREN E, PAPADIAMANTIS J, VASSILAROS SD, WILDIERS J AND WINTER PJ. (1989). Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur. J. Cancer Clin. Oncol., 25, 667-678.
27. SCHAAKE-KONING CCE, HAMERSMA VAN DER LINDEN E, HART G AND ENGELSMAN E. (1985). Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int. J. Radiat. Oncol. Biol. Phys., 11, 1759-1763.
28. SCHNITT SJ, SILEN W, SADOWSKY NL, CONNOLLY JL AND HARRIS JR. (1988). Ductal carcinoma in situ (intraductal carcinoma) of the breast. N. Engl. J. Med., 318, 898-903.
29. SMITH IE, WALSH G, JONES A, PRENDVILLE J, JOHNSTON S, GUSTERSON B, RAMAGE F, ROBERTSHAW H, SACKS N, EBBS S, MCKINNA JA AND BAUM M. (1995). High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J. Clin. Oncol., 13, 424-429.
30. TOUBOUL E, LEFRANC JP, BLONDON J, OZSAHIN M, MAUBAN S, SCHWARTZ LH, SCHLIENGER M, LAUGIER A AND GUERIN RA. (1992). Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother. Oncol., 25, 167-175.
31. 4 breast cancer: factors affecting results in combined modality treatments. Clin. Exp. Metastasis, 1, 191-202.
32. VALAGUSSA P, ZAMBETTI M, BONADONNA G, ZUCALI R, MEZZANOTTE G AND VERONESI U. (1990). Prognostic factors in locally advanced noninflammatory breast cancer. Long term results following primary chemotherapy. Breast Cancer Res. Treat., 15, 137-147.
33. VAN DER WALL E, RICHEL DJ, KUSUMANTO YH, RUTGERS EJT, SCHORNAGEL JH, SCHAAKE-KONING CCE, PETERSE JL AND RODENHUIS S. (1992). Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann. Oncol., 4, 791-792.
34. VAN DER WALL E, NOOIJEN WJ, BAARS JW, HOLTKAMP MJ, SCHORNAGEL JH, RICHEL DJ, RUTGERS EJT, SLAPER-CORTENBACH ICM, VAN DER SCHOOT CE AND RODENHUIS S. (1995). High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br. J. Cancer, 71, 857-862.